3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Iveson, TJ; Kerr, RS; Saunders, MP; Cassidy, J; Henrik Hollander, N; Tabernero, J; Haydon, A; ... Paul, J; + view all Iveson, TJ; Kerr, RS; Saunders, MP; Cassidy, J; Henrik Hollander, N; Tabernero, J; Haydon, A; Glimelius, B; Harkin, A; Allan, K; McQueen, J; Scudder, C; Boyd, KA; Briggs, A; Waterston, A; Medley, L; Wilson, C; Ellis, R; Essapen, S; Dhadda, AS; Harrison, M; Falk, S; Raouf, S; Rees, C; Olesen, RK; Propper, D; Bridgewater, J; Azzabi, A; Farrugia, D; Webb, A; Cunningham, D; Hickish, T; Weaver, A; Gollins, S; Wasan, HS; Paul, J; - view fewer (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology , 19 (4) pp. 562-578. 10.1016/S1470-2045(18)30093-7 . Green open access

https://ift.tt/2GV9Du1